Cargando…
The reversible P2Y(12) antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat
The P2Y(12) receptor is a validated target for prevention of major adverse cardiovascular events in patients with acute coronary syndrome. The aim of this study was to compare two direct‐acting, reversible P2Y(12) antagonists, ACT‐246475 and ticagrelor, in a rat thrombosis model by simultaneous quan...
Autores principales: | Rey, Markus, Kramberg, Markus, Hess, Patrick, Morrison, Keith, Ernst, Roland, Haag, Franck, Weber, Edgar, Clozel, Martine, Baumann, Martine, Caroff, Eva, Hubler, Francis, Riederer, Markus A., Steiner, Beat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625150/ https://www.ncbi.nlm.nih.gov/pubmed/28805949 http://dx.doi.org/10.1002/prp2.338 |
Ejemplares similares
-
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
por: Crescence, Lydie, et al.
Publicado: (2021) -
Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013) -
Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ET(A) Versus ET(B) Receptors and on the Functionality of Endothelial ET(B) Receptors
por: Iglarz, Marc, et al.
Publicado: (2015) -
Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties
por: Piali, Luca, et al.
Publicado: (2017) -
Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021)